Albireo Pharma (ALBO) Stock Rating Reiterated by Analysts at Wedbush; The $63.0 Target Indicates 71.10% Potential; MY Size (MYSZ) Shorts Increased By 20.05%

Among 6 analysts covering Albireo Pharma (ALBO), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Albireo Pharma has $92 highest and $35.0 lowest target. $57.50’s average target is 56.17% above currents $36.82 stock price. Albireo Pharma had 14 analyst reports since January 25, 2017 according to SRatingsIntel. Wedbush maintained Albireo Pharma, Inc. (NASDAQ:ALBO) on Monday, September 11 with “Buy” rating. Ladenburg Thalmann initiated the shares of ALBO in report on Thursday, February 16 with “Buy” rating. Wedbush maintained Albireo Pharma, Inc. (NASDAQ:ALBO) rating on Friday, January 19. Wedbush has “Buy” rating and $63.0 target. The firm has “Buy” rating by Needham given on Monday, August 21. The firm has “Buy” rating by Needham given on Tuesday, November 14. Wedbush maintained Albireo Pharma, Inc. (NASDAQ:ALBO) on Wednesday, January 3 with “Buy” rating. On Thursday, December 7 the stock rating was maintained by Wedbush with “Buy”. The firm has “Buy” rating by Wedbush given on Tuesday, October 24. The firm has “Buy” rating by Needham given on Tuesday, October 3.

MY Size Incorporated (NASDAQ:MYSZ) had an increase of 20.05% in short interest. MYSZ’s SI was 464,100 shares in January as released by FINRA. Its up 20.05% from 386,600 shares previously. With 2.37 million avg volume, 0 days are for MY Size Incorporated (NASDAQ:MYSZ)’s short sellers to cover MYSZ’s short positions. The stock increased 12.66% or $0.3 during the last trading session, reaching $2.67. About 10.42 million shares traded or 116.60% up from the average. My Size, Inc. (NASDAQ:MYSZ) has 0.00% since January 27, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock increased 8.29% or $2.82 during the last trading session, reaching $36.82. About 136,902 shares traded or 163.63% up from the average. Albireo Pharma, Inc. (ALBO) has risen 91.72% since January 27, 2017 and is uptrending. It has outperformed by 75.02% the S&P500.

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders in the United States. The company has market cap of $327.68 million. The Company’s lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis. It currently has negative earnings. The companyÂ’s clinical-stage product candidates comprise Elobixibat, an orally administered IBAT inhibitor, which is in Phase III clinical trial for the treatment of chronic constipation and other GI diseases; and A3384, a development stage product to treat bile acid malabsorption.

My Size, Inc., a technology company, engages in the development of applications primarily for apparel business in Israel. The company has market cap of $63.99 million. It offers MySizeID, an application, which enables clients to create a secure online profile of their personal measurements to get the right fit; and TrueSize, a mobile application that enables retailers to enhance the online shopping experience of their clients by matching their true measurements with the retailerÂ’s offerings, as well as SizeUp app, which allows users to utilize their smartphone as a tape measurer. It currently has negative earnings. The firm was formerly known as Knowledgetree Ventures, Inc. and changed its name to My Size, Inc. in January 2014.